Damora Therapeutics Inc (DMRA)
Damora Therapeutics Inc is a Nasdaq-listed common equity security tied to a biotechnology company focused on developing therapies for hematologic disorders. The company’s pipeline includes DMR-001, an investigational monoclonal antibody designed to target CALR mutations for essential thrombocythemia, as well as DMR-002 and DMR-003, which are anti-mutCALR therapies intended to address the broader mutCALR MPN patient population. Damora is also advancing GB3226, a small-molecule inhibitor of ENL-YEATS and FLT3 being developed for acute myeloid leukemia. Founded in 2011, the company is headquartered in Waltham, Massachusetts, and its development efforts span Denmark and North America.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DMRA
|
$19.61
|
-42.2% Downside
|
Overvalued
|
$43.38
|
27.9% Upside
|
Undervalued
|
Good
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
-8.9x
|
5.5x
|
—
|
2.031 B
|
1.681 B
|
0.0%
|
67.0%
|
50.5
|
—
|
10.6%
|
